Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.
Leuk Lymphoma. 2021 Sep;62(9):2227-2234. doi: 10.1080/10428194.2021.1907370. Epub 2021 Apr 2.
Serum and urine protein electrophoresis (sPEP/uPEP) are the standard methods for monitoring of multiple myeloma (MM). However, a method of detection with shorter half-life, such as serum-free light chain (FLC), could detect the response or progression earlier. In total, 450 MM patients were assessed in first, second, and third line. Response and progression were classified according to International myeloma working group guidelines. The overall median time to partial response or better was detectable significantly earlier with involved free light chain (iFLC) 1.94 months (IQR: 1.61-2.23) compared to sPEP 5.39 months (IQR: 3.88-7.00). In first line, iFLC detected progression earlier compared to sPEP, particularly in patients with progression more than 18 months after best response. In conclusion, a response observed by iFLC occurs at least a median of 3 months before response is detected by sPEP/uPEP.
血清和尿液蛋白电泳(sPEP/uPEP)是监测多发性骨髓瘤(MM)的标准方法。然而,半衰期更短的检测方法,如血清游离轻链(FLC),可以更早地检测到反应或进展。总共评估了 450 例一线、二线和三线 MM 患者。根据国际骨髓瘤工作组指南对反应和进展进行分类。与 sPEP 相比,受累游离轻链(iFLC)可更早检测到部分缓解或更好的总体中位时间为 1.94 个月(IQR:1.61-2.23),而 sPEP 为 5.39 个月(IQR:3.88-7.00)。在一线治疗中,iFLC 比 sPEP 更早检测到进展,尤其是在最佳反应后 18 个月以上进展的患者中。总之,与 sPEP/uPEP 相比,iFLC 检测到的反应至少早 3 个月。